Skin and hair peptides

The FDA regulates drugs and cosmetics under different parts of the Federal Food, Drug, and Cosmetic Act ^[7][8]. A product becomes a drug — and triggers the FDA's pre-market approval requirements, 503A/503B compounding rules, and the rest of the architecture covered in our compounded vs branded peptides explainer — only if it is intended to diagnose, cure, mitigate, treat, or prevent a disease, or intended to affect the structure or function of the body.

A skincare product containing a peptide ingredient operates as a cosmetic as long as its labeling and marketing stay within cosmetic claims (cleansing, beautifying, promoting attractiveness, altering appearance) and avoid drug claims (treating wrinkles as a medical condition, regrowing hair as a medical condition, healing wounds, etc.). FDA does not require pre-market approval for cosmetics, but it does require accurate labeling, INCI (International Nomenclature of Cosmetic Ingredients) ingredient declaration, and absence of false or misleading claims ^[8].

This is why GHK-Cu, Argireline, Matrixyl, and palmitoyl-peptide derivatives appear in thousands of commercial skincare products globally without any FDA "approval" — they are cosmetic ingredients, regulated as cosmetics, doing the regulatory thing cosmetics do. The same compound becomes a drug the moment a product is marketed with explicit therapeutic claims (treating a wound, regrowing hair as a medical condition, reversing photoaging as a disease). At that point the FDA drug architecture applies. PTD-DBM, by contrast, sits in active drug development for hair regrowth as a specific clinical indication — that is a different track.

GHK-Cu (copper tripeptide-1, glycyl-L-histidyl-L-lysine bound to copper) is the most extensively studied compound in this category. The molecule was first identified by Loren Pickart in the early 1970s as a wound-healing factor in human plasma. The basic mechanism is well-mapped: GHK-Cu modulates collagen and elastin gene expression, stimulates fibroblast proliferation, suppresses tumor-necrosis-factor-alpha and other inflammatory mediators, and has documented in-vitro effects on a broad set of skin and connective tissue pathways.

The 2018 IJMS review by Pickart and colleagues — the closest thing to a single canonical source on the compound — surveys the gene-data picture in detail ^[1]. A 2020 Aging Pathobiology and Therapeutics review covers the anti-aging mechanism arguments ^[2]. A 2025 BioImpacts review specifically addresses topical applications and the formulation challenges that affect skin penetration ^[3].

The honest editorial read: the mechanism is real. The in-vitro and ex-vivo data are consistent. The human clinical-trial data on hard cosmetic-outcome measures (wrinkle depth, elasticity, skin density) is positive but generally from small studies, with the larger and more rigorously designed studies in dermatology generally showing modest rather than dramatic effect sizes. GHK-Cu in a well-formulated topical at appropriate concentration is a reasonable cosmetic ingredient. GHK-Cu marketed as a "regenerative anti-aging therapy" with claims approaching drug-level efficacy is marketing copy outrunning the data.

The compound is also occasionally sold as an injectable through compounding pharmacies for indications outside the cosmetic frame (wound healing, tissue repair). That use case operates under 503A compounding architecture and is not the typical use case — it is also not supported by the same clinical-trial dataset as the topical cosmetic use.

Argireline (acetyl hexapeptide-8) is an N-terminal fragment mimic of the SNAP-25 protein. The marketing framing is that Argireline produces a botulinum-toxin-like effect by interfering with SNARE-complex assembly and reducing neurotransmitter release at facial muscle synapses — "Botox in a bottle," in the consumer-press version.

The biological reality is more limited. Botulinum toxin is an enzymatically active protein delivered by injection into target muscles at picomolar potency. Argireline is a topically applied peptide of much lower potency, with a meaningful skin-penetration challenge, and with mechanism-of-action evidence drawn mostly from in-vitro assays rather than confirmed neuromuscular effects in human skin. The 2024 Skin Research and Technology cosmeceuticals review covers the broader picture honestly ^[4].

There is real evidence that topical Argireline can produce modest, statistically detectable wrinkle reduction in well-controlled studies. There is not credible evidence that it produces effects approaching what injected botulinum toxin produces, despite the marketing frame. Reasonable expectation: a cosmetic ingredient with a measurable but modest effect, useful as part of a well-formulated routine, not as a substitute for in-office aesthetic treatments. The 2022 Survey of Ophthalmology review on periocular treatment complications ^[5] is worth knowing about for any consumer considering aggressive eyelid-area cosmetic use.

"Matrixyl" is a Sederma-branded ingredient family that includes palmitoyl pentapeptide-4 (Matrixyl), palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, and combinations marketed as Matrixyl 3000 and Matrixyl Synthe'6. The palmitoyl prefix denotes a fatty-acid modification that improves skin penetration of an otherwise hydrophilic peptide sequence.

The mechanism rationale: palmitoyl pentapeptide-4 mimics a fragment of type-I procollagen and is hypothesized to stimulate collagen synthesis through feedback regulation. Cosmetic-industry studies — most sponsored by Sederma or formulator partners — report measurable improvement in wrinkle depth and skin elasticity over treatment courses of several weeks to months.

The honest read: this is a reasonable cosmetic ingredient with industry-funded but not entirely independent evidence behind it. The 2024 Skin Research and Technology cosmeceuticals review covers palmitoyl peptides among other topical compounds ^[4]. As with Argireline, the effect size is real but modest; consumers expecting dramatic results in weeks are responding to marketing copy rather than the published evidence.

PTD-DBM (Protein Transduction Domain — Dvl Binding Motif) is a synthetic peptide that disrupts the interaction between Dishevelled and CXXC5, two proteins in the Wnt/β-catenin signaling pathway. The 2025 Cells review on hair regrowth, follicle neogenesis, and Wnt/β-catenin signaling covers the broader biological program ^[6].

The compound is in clinical development for androgenetic alopecia in South Korea, with academic and commercial partners (the original mechanism work came out of Kang-Yell Choi's group at Yonsei University). Early-stage clinical data has been reported in Korean academic and conference settings; the development pathway has not advanced to US FDA regulatory submissions as of mid-2026. There is no FDA-approved PTD-DBM product, and the compound is not appropriate for off-label use outside a clinical-trial setting.

The frame to use: PTD-DBM is a developmental drug, not a cosmetic ingredient. Treating it as the latter — buying research-chemical-supplied PTD-DBM and applying it topically as a hair-regrowth treatment — is using an unapproved drug for an unapproved indication, with no quality oversight on the source product. We would not recommend it.

Two points worth carrying out of this category.

The "more is better" instinct does not apply to cosmetic peptides. The active concentrations at which GHK-Cu, Argireline, and palmitoyl peptides have demonstrated effects in published studies are within reasonable formulation ranges (typically below 5% w/w for most peptides). Higher concentrations in compounded preparations do not have linear dose-response curves — and at high concentrations, formulation stability, skin irritation, and ingredient interactions become problems. Established cosmetic formulators choose concentrations that match the published effective range, not the highest the supply chain can deliver.

Compounded injectable cosmetic peptides are a different category from topical cosmetic peptides. When a cosmetic-grade ingredient like GHK-Cu is sold as an injectable through a compounding pharmacy or research-chemical supplier, the regulatory category shifts from cosmetic to drug — and the patient is operating under 503A or research-chemical norms, not under the cosmetic-product regulations that supported the ingredient's safety record. The clinical-trial evidence base for injectable GHK-Cu is much thinner than the evidence for topical GHK-Cu, and the risk profile is different.

Skin-and-hair peptides are not the focus of any of the telehealth providers PeptideWellness covers in our reviews. The mainstream commercial supply is through cosmetic-product channels — dermatology brands, prestige skincare lines, and direct-to-consumer formulator brands — not through telehealth platforms or compounding pharmacies.

For consumers evaluating cosmetic skincare products containing these peptides, the standard cosmetic-shopping disciplines apply: INCI labeling at the listed concentration (where disclosed), formulator transparency, third-party testing where the brand provides it, and skepticism of any claim that approaches drug-level efficacy.

For PTD-DBM specifically: wait for the clinical trial program to mature; if a hair-regrowth indication advances to a US approval pathway, that will be the appropriate access route.